November 10, 2020 -- CollPlant, a regenerative medicine company, is developing an antiviral agent for the potential treatment of COVID-19 patients. Early in vitro results suggest that CollPlant's formulation inhibits avian coronavirus infectivity.
The agent is based on the company's proprietary recombinant human type I collagen (rhCollagen) embedded with silver nanoparticles (AgNP). CollPlant produces the product on its plant-based genetic engineering technology.
The antiviral treatment is being evaluated in vitro using avian coronavirus grown on epithelial cells as a model of human coronavirus SARS-CoV-2. Efficacy of the treatment was assessed for the ability to protect epithelial cells from lethal doses of the virus. The results found a significant reduction in infectivity of the model with the rhCollagen-AgNP complexes.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
